Literature DB >> 7542228

Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer.

M Toi1, S Hoshina, T Taniguchi, Y Yamamoto, H Ishitsuka, T Tominaga.   

Abstract

We have investigated the expression of platelet-derived endothelial-cell growth factor/thymidine phosphorylase (PD-ECGF/dThdPase) in human breast-cancer tissues by the immunocytochemical method using anti-PD-ECGF/dThdPase monoclonal antibody. Out of 100 invasive-ductal-carcinoma tissue samples, 39 (39%) were evaluated as PD-ECGF/dThdPase-positive. The expression of PD-ECGF/dThdPase was identified mainly in the cytoplasma of tumor cells. The expression of PD-ECGF/dThdPase was significantly associated with the microvessel density assessed by immunostaining to factor-VIII-related-antigen (p < 0.05). However, there was no correlation between expression of PD-ECGF/dThdPase and menopausal status, tumor size, axillary lymph-node metastases, hormone-receptor status, epidermal-growth-factor receptor, or erb-B-2-protein and p53-protein expression. We suggest that expression of PD-ECGF/dThdPase plays an important role in the promotion of angiogenesis in human breast cancer.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7542228     DOI： 10.1002/ijc.2910640202

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


  24 in total

1.  Thymidine phosphorylase expression in endometrial carcinomas.

Authors:  E Sivridis; A Giatromanolaki; M I Koukourakis; R Bicknell; A L Harris; K C Gatter
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

2.  Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.

Authors:  R Fujiwaki; K Hata; K Iida; Y Maede; M Koike; K Miyazaki
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

3.  Angiogenesis and inflammation in invasive carcinoma of the breast.

Authors:  A H Lee; L C Happerfield; L G Bobrow; R R Millis
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

Review 4.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.

Authors:  S B Fox; A L Harris
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

5.  Prognostic significance of thymidine phosphorylase in superficial bladder carcinoma.

Authors:  N E Stavropoulos; C Bouropoulos; E Ioachim; M Michael; K Hastazeris; I Tsimaris; D Kalogeras; Z Liamis; V Kafarakis; S Stefanaki; V Malamou-Mitsi
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 6.  Structural analyses reveal two distinct families of nucleoside phosphorylases.

Authors:  Matthew J Pugmire; Steven E Ealick
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

7.  Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.

Authors:  Naoya Himuro; Yumiko Niiya; Takao Minakata; Yutaka Oshima; Daisuke Kataoka; Shigeru Yamamoto; Takashi Suzuki; Mitsutaka Kadokura
Journal:  Mol Clin Oncol       Date:  2018-09-25

Review 8.  Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience.

Authors:  Karen S Blesch; Ronald Gieschke; Yuko Tsukamoto; Bruno G Reigner; Hans U Burger; Jean-Louis Steimer
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 9.  Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis.

Authors:  N S Brown; R Bicknell
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

10.  Tumor cell motility and metastasis : Autocrine motility factor as an example of ecto/exoenzyme cytokines.

Authors:  S Silletti; S Paku; A Raz
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.